Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
June 24, 2020
Redoxis

Redoxis announces approved Eurostars funding for project E!114520 – ACTION

Redoxis announces approved Eurostars funding for project E!114520 – ACTION

-
Redoxis
-
June 24, 2020

We are very happy to announce that our joint project application E!114520 ACTION has been approved as a Eurostars labelled project and funding by the EUREKA Association. The project consortium is focused on development of hormone analogue drugs for treatment of autoimmune diseases. The novel drug will target the endocrine-immune interphase and the strong relationship between the level of hormones and symptom severity of autoimmune diseases such as Rheumatoid Arthritis (RA). The goal of the project is to develop a modified hormone based drugs that selectively targets immune cells without interfering with reproductive hormones. Redoxis role in the project, with a total budget of 1,6 million Euros and duration of 36 months, will be focused on evaluation of the effects of the developed drug candidates in autoimmunity using our established preclinical model platform. By combining niched and specific competences of the consortium members we aim to deliver an IND approved drug ready for first-in-human trials post-project.

Last updated:
June 24, 2020

Redoxis

Redoxis performs tailor-made preclinical studies combining dedication, experience and agility to provide reliable results to your project.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

We are very happy to announce that our joint project application E!114520 ACTION has been approved as a Eurostars labelled project and funding by the EUREKA Association. The project consortium is focused on development of hormone analogue drugs for treatment of autoimmune diseases. The novel drug will target the endocrine-immune interphase and the strong relationship between the level of hormones and symptom severity of autoimmune diseases such as Rheumatoid Arthritis (RA). The goal of the project is to develop a modified hormone based drugs that selectively targets immune cells without interfering with reproductive hormones. Redoxis role in the project, with a total budget of 1,6 million Euros and duration of 36 months, will be focused on evaluation of the effects of the developed drug candidates in autoimmunity using our established preclinical model platform. By combining niched and specific competences of the consortium members we aim to deliver an IND approved drug ready for first-in-human trials post-project.

Last updated:
June 24, 2020

Redoxis

Redoxis performs tailor-made preclinical studies combining dedication, experience and agility to provide reliable results to your project.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail